FibroGen, Inc. (FGEN)
NASDAQ: FGEN · Real-Time Price · USD
0.350
0.00 (0.00%)
Nov 20, 2024, 4:00 PM EST - Market open
FibroGen Revenue
FibroGen had revenue of $46.33M in the quarter ending September 30, 2024, with 15.45% growth. This brings the company's revenue in the last twelve months to $180.02M, up 16.15% year-over-year. In the year 2023, FibroGen had annual revenue of $147.75M with 4.99% growth.
Revenue (ttm)
$180.02M
Revenue Growth
+16.15%
P/S Ratio
0.19
Revenue / Employee
$370,401
Employees
486
Market Cap
36.36M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 147.75M | 7.02M | 4.99% |
Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
Dec 31, 2019 | 256.58M | 43.62M | 20.48% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DIH Holding US | 72.41M |
Barinthus Biotherapeutics | 14.97M |
Co-Diagnostics | 7.32M |
Dyadic International | 3.36M |
Adagio Medical Holdings | 543.00K |
FGEN News
- 8 days ago - FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 8 days ago - FibroGen Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 16 days ago - FibroGen to Report Third Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program - Benzinga
- 4 months ago - FibroGen to Report Second Quarter 2024 Financial Results - GlobeNewsWire
- 6 months ago - FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward - Seeking Alpha
- 6 months ago - FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials - GlobeNewsWire